Loading
The MSKCC (Motzer) model sorts advanced kidney cancer into favourable, intermediate and poor risk by counting five factors; the IMDC model later replaced it, but trials and labels still use it.
From 670 patients with advanced renal cell carcinoma in 24 Memorial Sloan-Kettering trials between 1975 and 1996, Motzer and colleagues (Journal of Clinical Oncology 1999) identified five factors linked to shorter survival: Karnofsky performance status below 80%, LDH above 1.5 times the upper limit of normal, haemoglobin below the lower limit of normal, corrected calcium above 10 mg/dl, and no prior nephrectomy. Patients with none were favourable risk (25% of patients, median survival 20 months in that era), one or two intermediate (53%, 10 months), and three or more poor (22%, 4 months). Survival with current immunotherapy combinations is far longer than in this pre-targeted-therapy cohort.
Renal cell carcinoma comes from the kidney's filtering cortex, urothelial cancer from the lining of the collecting system and bladder, and the adrenal on top hosts cortical and medullary (neuroblastoma) tumours.
Same organ: Collecting duct carcinoma of the kidney, Renal medullary carcinoma (SMARCB1-deficient), TFE3-rearranged (translocation) renal cell carcinoma, Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated), Succinate dehydrogenase-deficient renal cell carcinoma, Mucinous tubular and spindle cell carcinoma of the kidney, Eosinophilic solid and cystic renal cell carcinoma, Clear cell papillary renal cell tumour, Urothelial carcinoma of the urethra, Squamous cell carcinoma of the urethra, Adenocarcinoma of the urethra (including clear cell adenocarcinoma), Melanoma of the urethra, Non-muscle-invasive bladder cancer, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Clear cell renal cell carcinoma, Papillary renal cell carcinoma, Chromophobe renal cell carcinoma, Wilms tumour (nephroblastoma), Neuroblastoma (paediatric), Low-risk neuroblastoma (INRG very low and low risk, including stage MS), Intermediate-risk neuroblastoma, High-risk neuroblastoma, Adrenocortical carcinoma, Pheochromocytoma and paraganglioma (PPGL), Urethral cancer, Penile cancer, Localised penile cancer (organ-confined, node-negative), Node-positive and metastatic penile cancer, Localised adrenocortical carcinoma (ENSAT stage I to III, resectable), Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable), Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127), Metastatic pheochromocytoma and paraganglioma
Showing the organ this term concerns: Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares IMDC risk groups (favourable / intermediate / poor), Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares IMDC risk groups (favourable / intermediate / poor), Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/